Boehringer Ingelheim Pharm., Inc. v. Fed. Trade Comm'n
136 S. Ct. 925, 193 L. Ed. 2d 790, 84 U.S.L.W. 3405, 2016 U.S. LEXIS 692
CourtSupreme Court of the United States
DecidedJanuary 19, 2016
DocketNo. 15–560.
StatusPublished
Cited by1 cases
This text of 136 S. Ct. 925 (Boehringer Ingelheim Pharm., Inc. v. Fed. Trade Comm'n) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
Boehringer Ingelheim Pharm., Inc. v. Fed. Trade Comm'n, 136 S. Ct. 925, 193 L. Ed. 2d 790, 84 U.S.L.W. 3405, 2016 U.S. LEXIS 692 (U.S. 2016).
Opinion
Petition for writ of certiorari to the United States Court of Appeals for the District of Columbia Circuit denied.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Federal Trade Commission v. Boehringer Ingelheim Pharmaceuticals, Inc.
241 F. Supp. 3d 91 (District of Columbia, 2017)
Cite This Page — Counsel Stack
Bluebook (online)
136 S. Ct. 925, 193 L. Ed. 2d 790, 84 U.S.L.W. 3405, 2016 U.S. LEXIS 692, Counsel Stack Legal Research, https://law.counselstack.com/opinion/boehringer-ingelheim-pharm-inc-v-fed-trade-commn-scotus-2016.